Sign In
Buy CRL
$179.87
+5.08 (+2.91%)
At Close: Jun 03, 2026
Charles River Laboratories Achieves 100% Renewable Electricity Usage Globally
08:00am, Monday, 22'nd Apr 2024
WILMINGTON, Mass.--(BUSINESS WIRE)---- $CRL #LIFEatCRL--In addition to advancing human health and improving quality of life, we are dedicated to a responsible tomorrow.
Here's Why You Should Retain Charles River (CRL) Stock Now
12:51pm, Tuesday, 16'th Apr 2024
Investors are optimistic about Charles River (CRL) owing to strength in RMS and DSA segments.
Charles River Laboratories Launches Alternative Methods Advancement Project to Reduce Reliance on Animal Testing
08:00am, Tuesday, 16'th Apr 2024
WILMINGTON, Mass.--(BUSINESS WIRE)---- $CRL #LIFEatCRL--Charles River launches the Alternative Methods Advancement Project (AMAP), an initiative to develop alternatives to reduce animal testing.
ICLR or CRL: Which Is the Better Value Stock Right Now?
12:41pm, Friday, 12'th Apr 2024
Investors looking for stocks in the Medical Services sector might want to consider either Icon PLC (ICLR) or Charles River Laboratories (CRL). But which of these two companies is the best option for t
Charles River Laboratories Schedules First-Quarter 2024 Earnings Release and Conference Call
08:00am, Friday, 12'th Apr 2024
WILMINGTON, Mass.--(BUSINESS WIRE)---- $CRL--Charles River Laboratories International, Inc. (NYSE: CRL) will release first-quarter 2024 financial results on Thursday, May 9th, before the market opens.
Charles River (CRL) Forges Collaboration With Ship of Theseus
10:10am, Thursday, 11'th Apr 2024
Charles River (CRL) is set to perform plasmid production for Ship of Theseus.
Charles River and Deciphex Launch Patholytix Foresight, a Transformative AI-Powered Decision Support Tool for Toxicologic Pathology
08:00am, Thursday, 11'th Apr 2024
WILMINGTON, Mass. & DUBLIN--(BUSINESS WIRE)---- $CRL #LIFEatCRL--Charles River and Deciphex launch Patholytix Foresight, an AI-powered decision support tool for toxicologic pathology.
Charles River Announces Rare Disease Gene Therapy Collaboration with Axovia Therapeutics
08:00am, Tuesday, 09'th Apr 2024
WILMINGTON, Mass.--(BUSINESS WIRE)--Charles River Laboratories International, Inc. (NYSE: CRL) today announced a plasmid DNA contract development and manufacturing organization (CDMO) collaboration wi
Charles River to Perform Plasmid Production for Ship of Theseus
08:00am, Thursday, 04'th Apr 2024
WILMINGTON, Mass.--(BUSINESS WIRE)--Charles River Laboratories International, Inc. (NYSE: CRL) and Ship of Theseus, a therapeutics company developing degradation-resistant homeobox (HOX) family biolog
Charles River Laboratories Publishes 2023 Corporate Citizenship Report
08:00am, Wednesday, 27'th Mar 2024
WILMINGTON, Mass.--(BUSINESS WIRE)--Charles River Laboratories International, Inc. (NYSE: CRL) today announced the publication of its 2023 Corporate Citizenship Report, which includes progress and res
Charles River (CRL) Extends Gene Therapy Deal With NUS Medicine
10:41am, Tuesday, 26'th Mar 2024
Charles River (CRL) announces the extension of the gene therapy manufacturing alliance with NUS Medicine.
Why Is Charles River (CRL) Up 6.2% Since Last Earnings Report?
12:36pm, Friday, 15'th Mar 2024
Charles River (CRL) reported earnings 30 days ago. What's next for the stock?
Charles River (CRL) Extends Gene Therapy Offering With New Pact
11:31am, Friday, 15'th Mar 2024
Charles River's (CRL) partnership with Navega Therapeutics will enable it to leverage its strong AAV portfolio and leading gene therapy CDMO capabilities.
Here's Why You Should Retain Charles River (CRL) Stock Now
10:51am, Thursday, 14'th Mar 2024
Investors remain optimistic about Charles River (CRL) due to the strength of the RMS segment.
Epic Bio to Present at the Upcoming Charles River Cell and Gene Therapy Summit
04:00pm, Wednesday, 13'th Mar 2024
SOUTH SAN FRANCISCO, Calif., March 13, 2024 (GLOBE NEWSWIRE) -- Epic Bio, a leading epigenetic editing company that plans to dose its first patients later this year, today announced that Amber Salzman
